Clinical Trial ResultsThe VAX-24 infant study missed post-dose 3 primary serotype conversion rate non-inferiority criteria on 4 of 24 serotypes relative to Prevnar 20.
Regulatory UncertaintyAnti-vaccine news flow and regulatory uncertainty out of HHS/FDA, including this week's appointment of Dr. Vinay Prasad as head of CBER, continue to put pressure on shares.
Stock Price TargetFollowing PCVX’s disappointing Ph2 VAX-24 infant data, the price target is reduced from $153 to $65.